Symbols / HRTX
HRTX Chart
About
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 199.87M |
| Enterprise Value | 292.68M | Income | -13.58M | Sales | 155.10M |
| Book/sh | 0.04 | Cash/sh | 0.30 | Dividend Yield | — |
| Payout | 0.00% | Employees | 122 | IPO | — |
| P/E | — | Forward P/E | -21.80 | PEG | — |
| P/S | 1.29 | P/B | 28.68 | P/C | — |
| EV/EBITDA | 74.00 | EV/Sales | 1.89 | Quick Ratio | 1.52 |
| Current Ratio | 2.56 | Debt/Eq | 943.52 | LT Debt/Eq | — |
| EPS (ttm) | -0.09 | EPS next Y | -0.05 | EPS Growth | — |
| Revenue Growth | 16.50% | Earnings | 2026-02-26 | ROA | 0.43% |
| ROE | — | ROIC | — | Gross Margin | 66.27% |
| Oper. Margin | -10.71% | Profit Margin | -8.76% | Shs Outstand | 183.36M |
| Shs Float | 128.57M | Short Float | 23.80% | Short Ratio | 21.75 |
| Short Interest | — | 52W High | 2.68 | 52W Low | 1.00 |
| Beta | 1.25 | Avg Volume | 1.59M | Volume | 2.68M |
| Target Price | $4.33 | Recom | Strong_buy | Prev Close | $1.19 |
| Price | $1.09 | Change | -8.40% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.33
Mean price target
2. Current target
$1.09
Latest analyst target
3. DCF / Fair value
$-3.32
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.09
Low
$3.00
High
$6.00
Mean
$4.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-09 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-08-08 | main | Needham | Buy → Buy | $3 |
| 2025-06-09 | init | HC Wainwright & Co. | — → Buy | $6 |
| 2025-04-11 | reit | Needham | Buy → Buy | $4 |
| 2025-02-28 | reit | Needham | Buy → Buy | $4 |
| 2024-12-04 | reit | Needham | Buy → Buy | $4 |
| 2024-11-13 | main | Needham | Buy → Buy | $4 |
| 2024-09-25 | reit | Needham | Buy → Buy | $5 |
| 2024-08-07 | reit | Needham | Buy → Buy | $5 |
| 2024-06-13 | init | Rodman & Renshaw | — → Buy | $7 |
| 2024-05-16 | reit | Needham | Buy → Buy | $5 |
| 2024-05-08 | reit | Needham | Buy → Buy | $5 |
| 2024-04-23 | init | Capital One | — → Overweight | $6 |
| 2024-04-11 | reit | Needham | Buy → Buy | $5 |
| 2024-03-13 | main | Needham | Buy → Buy | $5 |
| 2023-11-15 | main | Needham | Buy → Buy | $4 |
| 2023-08-15 | reit | Needham | Buy → Buy | $5 |
| 2023-07-25 | main | Needham | Buy → Buy | $5 |
| 2023-05-12 | main | Needham | Buy → Buy | $6 |
| 2023-04-21 | reit | Needham | — → Buy | $7 |
- Heron Therapeutics, Inc. (HRTX) Stock Analysis: Exploring A Potential Upside Of 258.13% - DirectorsTalk Interviews Fri, 20 Feb 2026 05
- Heron: Near The Bottom Of A Trading Range Despite Positives (NASDAQ:HRTX) - Seeking Alpha Wed, 18 Feb 2026 15
- Heron Therapeutics, Inc. $HRTX Shares Acquired by JW Asset Management LLC - MarketBeat hu, 19 Feb 2026 13
- Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Catapults 27% Though Its Price And Business Still Lag The Industry - simplywall.st ue, 16 Dec 2025 08
- Heron Therapeutics, Inc. (NASDAQ:HRTX) is favoured by institutional owners who hold 57% of the company - Yahoo Finance Mon, 15 Dec 2025 08
- Heron Therapeutics (NASDAQ: HRTX) to report third‑quarter results Nov. 4 at 8:30 a.m. ET - Stock Titan ue, 21 Oct 2025 07
- Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 - GlobeNewswire ue, 17 Feb 2026 13
- $HRTX stock is up 12% today. Here's what we see in our data. - Quiver Quantitative Fri, 09 Jan 2026 08
- Is Heron Therapeutics Stock Built to Withstand More Downside? - Trefis Sun, 21 Dec 2025 08
- Rubric capital buys Heron Therapeutics (HRTX) shares worth $3.5m - Investing.com ue, 12 Aug 2025 07
- Heron Therapeutics (HRTX) Expected to Announce Earnings on Thursday - MarketBeat hu, 19 Feb 2026 08
- Heron Therapeutics (HRTX): Forecasts Signal 60.89% Annual Earnings Growth, Path to Profitability in Focus - Yahoo Finance ue, 04 Nov 2025 08
- Market Sentiment Around Loss-Making Heron Therapeutics, Inc. (NASDAQ:HRTX) - simplywall.st Fri, 05 Dec 2025 08
- Pain and nausea drugs help a biotech boost sales at end of 2025 - Stock Titan Fri, 09 Jan 2026 08
- Heron Therapeutics: The View From 30,000 Feet Amid The Zynrelef Launch (NASDAQ:HRTX) - Seeking Alpha Mon, 25 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 53960 | — | — | Stock Award(Grant) at price 0.00 per share. | CUSACK THOMAS J | Director | — | 2026-01-30 00:00:00 | D |
| 1 | 11695 | nan | — | — | FORBES WILLIAM P | Officer | — | 2026-01-30 00:00:00 | D |
| 2 | 34789 | nan | — | — | COLLARD CRAIG ALEXANDER | Chief Executive Officer | — | 2026-01-30 00:00:00 | D |
| 3 | 53960 | — | — | Stock Award(Grant) at price 0.00 per share. | JOHNSON CRAIG A | Director | — | 2026-01-30 00:00:00 | D |
| 4 | 11695 | nan | — | — | DUARTE IRA | Chief Financial Officer | — | 2026-01-30 00:00:00 | D |
| 5 | 53960 | — | — | Stock Award(Grant) at price 0.00 per share. | KASETA MICHAEL | Director | — | 2026-01-30 00:00:00 | D |
| 6 | 53960 | — | — | Stock Award(Grant) at price 0.00 per share. | DISSANAIKE SHARMILA | Director | — | 2026-01-30 00:00:00 | D |
| 7 | 53960 | — | — | Stock Award(Grant) at price 0.00 per share. | MORGAN ADAM | Director | — | 2026-01-30 00:00:00 | D |
| 8 | 53960 | — | — | Stock Award(Grant) at price 0.00 per share. | CHRISTIAN WAAGE | Director | — | 2026-01-30 00:00:00 | D |
| 9 | 3875 | nan | — | — | FORBES WILLIAM P | Officer | — | 2026-01-16 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -5.06M | -103.79M | -176.66M | -215.25M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -13.58M | -110.56M | -182.02M | -220.68M |
| ReconciledDepreciation | 2.49M | 2.90M | 2.89M | 3.02M |
| ReconciledCostOfRevenue | 38.65M | 65.11M | 54.87M | 46.02M |
| EBITDA | -5.06M | -103.79M | -176.66M | -215.25M |
| EBIT | -7.55M | -106.69M | -179.55M | -218.27M |
| NetInterestIncome | -2.48M | -504.00K | -836.00K | -1.98M |
| InterestExpense | 6.03M | 3.87M | 2.47M | 2.41M |
| InterestIncome | 3.55M | 3.36M | 1.64M | 433.00K |
| NormalizedIncome | -13.58M | -110.56M | -182.02M | -220.68M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -13.58M | -110.56M | -182.02M | -220.68M |
| TotalExpenses | 155.81M | 237.66M | 282.33M | 304.17M |
| TotalOperatingIncomeAsReported | -11.53M | -110.61M | -174.66M | -217.83M |
| DilutedAverageShares | 152.45M | 138.13M | 109.00M | 98.47M |
| BasicAverageShares | 152.45M | 138.13M | 109.00M | 98.47M |
| DilutedEPS | -0.09 | -0.80 | -1.67 | -2.24 |
| BasicEPS | -0.09 | -0.80 | -1.67 | -2.24 |
| DilutedNIAvailtoComStockholders | -13.58M | -110.56M | -182.02M | -220.68M |
| NetIncomeCommonStockholders | -13.58M | -110.56M | -182.02M | -220.68M |
| NetIncome | -13.58M | -110.56M | -182.02M | -220.68M |
| NetIncomeIncludingNoncontrollingInterests | -13.58M | -110.56M | -182.02M | -220.68M |
| NetIncomeContinuousOperations | -13.58M | -110.56M | -182.02M | -220.68M |
| PretaxIncome | -13.58M | -110.56M | -182.02M | -220.68M |
| OtherIncomeExpense | 430.00K | 560.00K | -6.53M | -878.00K |
| OtherNonOperatingIncomeExpenses | 430.00K | 560.00K | -6.53M | -878.00K |
| NetNonOperatingInterestIncomeExpense | -2.48M | -504.00K | -836.00K | -1.98M |
| InterestExpenseNonOperating | 6.03M | 3.87M | 2.47M | 2.41M |
| InterestIncomeNonOperating | 3.55M | 3.36M | 1.64M | 433.00K |
| OperatingIncome | -11.53M | -110.61M | -174.66M | -217.83M |
| OperatingExpense | 117.17M | 172.55M | 227.46M | 258.15M |
| ResearchAndDevelopment | 16.68M | 39.13M | 82.70M | 130.82M |
| SellingGeneralAndAdministration | 100.48M | 133.42M | 144.75M | 127.33M |
| SellingAndMarketingExpense | 47.09M | 67.64M | 82.51M | 87.18M |
| GeneralAndAdministrativeExpense | 53.40M | 65.78M | 62.24M | 40.15M |
| OtherGandA | 53.40M | 65.78M | 62.24M | 40.15M |
| GrossProfit | 105.64M | 61.94M | 52.80M | 40.33M |
| CostOfRevenue | 38.65M | 65.11M | 54.87M | 46.02M |
| TotalRevenue | 144.28M | 127.04M | 107.67M | 86.35M |
| OperatingRevenue | 144.28M | 127.04M | 107.67M | 86.35M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 152.13M | 150.29M | 119.16M | 102.00M |
| ShareIssued | 152.13M | 150.29M | 119.16M | 102.00M |
| NetDebt | 148.92M | 145.08M | 133.92M | 58.54M |
| TotalDebt | 177.76M | 179.63M | 157.48M | 159.50M |
| TangibleBookValue | -33.65M | -33.97M | 13.57M | 77.57M |
| InvestedCapital | 141.07M | 139.78M | 162.86M | 226.65M |
| WorkingCapital | 117.56M | 109.09M | 123.08M | 183.37M |
| NetTangibleAssets | -33.65M | -33.97M | 13.57M | 77.57M |
| CapitalLeaseObligations | 3.04M | 5.88M | 8.19M | 10.41M |
| CommonStockEquity | -33.65M | -33.97M | 13.57M | 77.57M |
| TotalCapitalization | 141.07M | 139.78M | 162.86M | 226.65M |
| TotalEquityGrossMinorityInterest | -33.65M | -33.97M | 13.57M | 77.57M |
| StockholdersEquity | -33.65M | -33.97M | 13.57M | 77.57M |
| GainsLossesNotAffectingRetainedEarnings | 13.00K | 13.00K | -19.00K | -6.00K |
| OtherEquityAdjustments | 13.00K | 13.00K | -19.00K | -6.00K |
| RetainedEarnings | -1.92B | -1.91B | -1.80B | -1.61B |
| AdditionalPaidInCapital | 1.88B | 1.87B | 1.81B | 1.69B |
| CapitalStock | 1.52M | 1.50M | 1.19M | 1.02M |
| CommonStock | 1.52M | 1.50M | 1.19M | 1.02M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 266.80M | 256.48M | 237.38M | 228.14M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 175.34M | 176.79M | 155.02M | 157.08M |
| OtherNonCurrentLiabilities | 615.00K | 241.00K | 241.00K | |
| LongTermDebtAndCapitalLeaseObligation | 174.73M | 176.55M | 154.78M | 157.08M |
| LongTermCapitalLeaseObligation | 0.00 | 2.80M | 5.50M | 8.00M |
| LongTermDebt | 174.73M | 173.75M | 149.28M | 149.08M |
| CurrentLiabilities | 91.46M | 79.69M | 82.36M | 71.06M |
| CurrentDebtAndCapitalLeaseObligation | 3.04M | 3.08M | 2.69M | 2.42M |
| CurrentCapitalLeaseObligation | 3.04M | 3.08M | 2.69M | 2.42M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 7.96M | 7.85M | 11.28M | 13.48M |
| PayablesAndAccruedExpenses | 80.46M | 68.76M | 68.38M | 55.16M |
| CurrentAccruedExpenses | 68.75M | 64.96M | 64.79M | 51.29M |
| InterestPayable | 237.00K | 412.00K | 94.00K | |
| Payables | 11.71M | 3.80M | 3.59M | 3.87M |
| AccountsPayable | 11.71M | 3.80M | 3.59M | 3.87M |
| TotalAssets | 233.15M | 222.51M | 250.95M | 305.71M |
| TotalNonCurrentAssets | 24.13M | 33.73M | 45.52M | 51.28M |
| OtherNonCurrentAssets | 6.48M | 8.13M | 15.71M | 17.72M |
| NetPPE | 17.65M | 25.60M | 29.80M | 33.56M |
| AccumulatedDepreciation | -17.85M | -17.03M | -14.29M | -13.24M |
| GrossPPE | 35.50M | 42.63M | 44.10M | 46.81M |
| Leases | 307.00K | 647.00K | 647.00K | 610.00K |
| OtherProperties | 33.13M | 39.47M | 40.96M | 43.23M |
| MachineryFurnitureEquipment | 2.06M | 2.52M | 2.49M | 2.96M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 209.01M | 188.77M | 205.44M | 254.42M |
| OtherCurrentAssets | 17.69M | 6.12M | 13.96M | 12.96M |
| PrepaidAssets | 12.96M | |||
| Inventory | 53.16M | 42.11M | 54.57M | 48.38M |
| FinishedGoods | 6.24M | 9.92M | 18.71M | 6.25M |
| WorkInProcess | 27.19M | 14.55M | 20.72M | 20.93M |
| RawMaterials | 19.73M | 17.64M | 15.14M | 21.19M |
| Receivables | 78.88M | 60.14M | 52.05M | 35.50M |
| AccountsReceivable | 78.88M | 60.14M | 52.05M | 35.50M |
| CashCashEquivalentsAndShortTermInvestments | 59.28M | 80.41M | 84.85M | 157.58M |
| OtherShortTermInvestments | 33.48M | 51.73M | 69.49M | 67.04M |
| CashAndCashEquivalents | 25.80M | 28.68M | 15.36M | 90.54M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -24.23M | -60.33M | -148.74M | -206.38M |
| IssuanceOfDebt | 0.00 | 24.35M | 0.00 | 148.96M |
| IssuanceOfCapitalStock | 0.00 | 29.75M | 75.14M | 0.00 |
| CapitalExpenditure | -1.71M | -1.54M | -1.82M | -3.02M |
| InterestPaidSupplementalData | 4.86M | 3.06M | 2.25M | 1.24M |
| EndCashPosition | 25.80M | 28.68M | 15.36M | 90.54M |
| BeginningCashPosition | 28.68M | 15.36M | 90.54M | 105.14M |
| ChangesInCash | -2.88M | 13.31M | -75.18M | -14.60M |
| FinancingCashFlow | 940.00K | 54.11M | 75.06M | 156.03M |
| CashFlowFromContinuingFinancingActivities | 940.00K | 54.11M | 75.06M | 156.03M |
| ProceedsFromStockOptionExercised | 940.00K | 2.00K | -86.00K | 7.07M |
| NetCommonStockIssuance | 0.00 | 29.75M | 75.14M | 0.00 |
| CommonStockIssuance | 0.00 | 29.75M | 75.14M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | 24.35M | 0.00 | 148.96M |
| NetLongTermDebtIssuance | 0.00 | 24.35M | 0.00 | 148.96M |
| LongTermDebtIssuance | 0.00 | 24.35M | 0.00 | 148.96M |
| InvestingCashFlow | 18.71M | 18.00M | -3.32M | 32.73M |
| CashFlowFromContinuingInvestingActivities | 18.71M | 18.00M | -3.32M | 32.73M |
| NetInvestmentPurchaseAndSale | 20.39M | 19.53M | -1.73M | 35.72M |
| SaleOfInvestment | 123.48M | 107.19M | 143.96M | 164.94M |
| PurchaseOfInvestment | -103.09M | -87.66M | -145.68M | -129.22M |
| NetPPEPurchaseAndSale | -1.68M | -1.53M | -1.60M | -2.99M |
| SaleOfPPE | 27.00K | 13.00K | 227.00K | 32.00K |
| PurchaseOfPPE | -1.71M | -1.54M | -1.82M | -3.02M |
| OperatingCashFlow | -22.53M | -58.79M | -146.91M | -203.35M |
| CashFlowFromContinuingOperatingActivities | -22.53M | -58.79M | -146.91M | -203.35M |
| ChangeInWorkingCapital | -27.60M | 16.79M | -10.51M | -35.08M |
| ChangeInPayablesAndAccruedExpense | 12.12M | -3.01M | 11.22M | -26.57M |
| ChangeInAccruedExpense | 3.65M | -3.03M | 11.80M | -29.84M |
| ChangeInPayable | 8.47M | 15.00K | -578.00K | 3.28M |
| ChangeInAccountPayable | 8.47M | 15.00K | -578.00K | 3.28M |
| ChangeInPrepaidAssets | -9.93M | 15.43M | 1.01M | -8.39M |
| ChangeInInventory | -11.05M | 12.46M | -6.19M | -6.48M |
| ChangeInReceivables | -18.74M | -8.09M | -16.55M | 6.35M |
| ChangesInAccountReceivables | -18.74M | -8.09M | -16.55M | 6.35M |
| OtherNonCashItems | 961.00K | 339.00K | 202.00K | 904.00K |
| StockBasedCompensation | 12.96M | 32.85M | 42.98M | 46.85M |
| AssetImpairmentCharge | 617.00K | 209.00K | 478.00K | |
| AmortizationOfSecurities | -2.14M | -1.74M | -736.00K | 332.00K |
| DepreciationAmortizationDepletion | 2.49M | 2.90M | 2.89M | 3.02M |
| DepreciationAndAmortization | 2.49M | 2.90M | 2.89M | 3.02M |
| OperatingGainsLosses | 4.38M | 627.00K | 283.00K | 822.00K |
| GainLossOnSaleOfPPE | 4.38M | 627.00K | 283.00K | 822.00K |
| NetIncomeFromContinuingOperations | -13.58M | -110.56M | -182.02M | -220.68M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for HRTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|